FTO ‐mediated m6A modification of protein disulfide‐isomerase activates VEGFA – VEGFR2 to suppress programmed cell death in osteosarcoma
The Journal of Pathology · 2026-09 · 270 (1) · 69-82
DOI: 10.1002/path.70083 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pathology, online erschienen am 05.06.2026. Verfasst von Jiashi Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Shengjing Hospital of China Medical University, Shenyang, PR China. Hauptthemen laut MEDLINE: Osteosarcoma, Bone Neoplasms, Apoptosis, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Natural Science Foundation of Liaoning Province, China, Joint Program of Science and Technology Plan of Liaoning Province (Natural Science Foundation General Project), 345 Talent Project of Shengjing Hospital.
Abstract (Originalsprache)
Osteosarcoma (OS) is a primary bone malignancy, and its progression can be hindered by inducing programmed cell death (PCD). Protein disulfide‐isomerase (PDI) regulates cancer cell death; however, its functional role in OS remains unclear. P4HB expression was assessed in tumor tissues and cells from patients with OS using RT‐qPCR. The effects of P4HB on OS cell lines were evaluated. Western blotting was used to assess the impact of P4HB on various forms of PCD (apoptosis, ferroptosis, and pyroptosis). Bioinformatics analysis identified the upstream and downstream mechanisms of P4HB in OS progression. A xenograft tumorigenesis study was performed to elucidate the role and mechanism of P4HB in OS progression. Elevated P4HB expression was observed in OS tissue samples and cell lines. Downregulation of P4HB suppressed OS cell growth, migration, and invasiveness and induced PCD. Functional enrichment analysis and experimental validation revealed that PDI upregulated vascular endothelial growth factor A (VEGFA) vascular endothelial growth factor receptor 2 (VEGFR2) signaling. Methylation analysis showed that the m6A demethylase fat mass and obesity‐associated protein (FTO) decreased P4HB m6A levels and enhanced VEGFA–VEGFR2 signaling in OS cells. Moreover, FTO overexpression enhanced the proliferative, migratory, and invasive capabilities of OS cells and decreased PCD. Finally, FTO knockdown inhibited tumor growth and lung metastasis of OS by decreasing the activity of the PDI/VEGFA–VEGFR2 signaling axis. Mechanistically, FTO ‐mediated m6A modification of P4HB regulates PCD in OS through activation of this axis. © 2026 The Pathological Society of Great Britain and Ireland.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, Shengjing Hospital of China Medical University, Shenyang, PR China.
- Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, PR China.
- Department of Pediatric Orthopaedics, Shengjing Hospital of China Medical University, Shenyang, PR China.
ORCID-Profile: Weizheng Zhou
Förderung
- Natural Science Foundation of Liaoning Province, China
- Joint Program of Science and Technology Plan of Liaoning Province (Natural Science Foundation General Project)
- 345 Talent Project of Shengjing Hospital
- Natural Science Foundation of Liaoning Province
Zitieren
APA
Wang, J., Hao, Y., He, M., & Zhou, W. (2026). FTO ‐mediated m6A modification of protein disulfide‐isomerase activates VEGFA – VEGFR2 to suppress programmed cell death in osteosarcoma. The Journal of Pathology, 270(1), 69-82. https://doi.org/10.1002/path.70083
Vancouver
Wang J, Hao Y, He M, Zhou W. FTO ‐mediated m6A modification of protein disulfide‐isomerase activates VEGFA – VEGFR2 to suppress programmed cell death in osteosarcoma. The Journal of Pathology. 2026;270(1):69-82. doi:10.1002/path.70083
BibTeX
@article{Wang2026,
author = {Wang, Jiashi and Hao, Yingying and He, Ming and Zhou, Weizheng},
title = {FTO ‐mediated m6A modification of protein disulfide‐isomerase activates VEGFA – VEGFR2 to suppress programmed cell death in osteosarcoma},
journal = {The Journal of Pathology},
year = {2026},
volume = {270},
number = {1},
pages = {69--82},
doi = {10.1002/path.70083}
}
EUVIMED